A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
Denise A. Yardley(Sarah Cannon), Dianna Shipley(Tennessee Oncology), John D. Zubkus(Tennessee Oncology), Gail Lynn Shaw Wright(Florida Cancer Specialists & Research Institute), Patrick J. Ward(Oncology Hematology Care), Aruna Mani(Memorial Healthcare System), Mythili Shastry(Sarah Cannon), Lindsey Finney(Sarah Cannon), Laura M. DeBusk(Sarah Cannon), John D. Hainsworth(Sarah Cannon)
Cited by 7
Abstract
Related Papers
No related papers found
Powered by citation graph analysis